CogState Limited provided earnings guidance for the second half and Full Year Ended June 30, 2017. For the second half, the company expected revenue from Clinical Trials of approximately AUD 16.2 million, a decrease of approximately AUD 2.2 million from the AUD 18.4 million Clinical Trials revenue recorded during the first half of the year. For the year, the company expected net loss, before tax, of approximately AUD 1.0 million for the full year ended 30 June 2017. Notwithstanding the expected loss, the company recorded a net cash inflow from operations. Cash reserves at 30 June 2017 were AUD 9.3 million, an increase of AUD 1.8 million during the year. Depreciation of AUD 1.0 million compared with AUD 0.9 million.